Back to Search Start Over

Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998-2012.

Authors :
Crocetti E
Mattioli V
Buzzoni C
Franceschi S
Serraino D
Vaccarella S
Ferretti S
Busco S
Fedeli U
Varvarà M
Falcini F
Zorzi M
Carrozzi G
Mazzucco W
Gasparotti C
Iacovacci S
Toffolutti F
Cavallo R
Stracci F
Russo AG
Caldarella A
Rosso S
Musolino A
Mangone L
Casella C
Fusco M
Tagliabue G
Piras D
Tumino R
Guarda L
Dinaro YM
Piffer S
Pinna P
Mazzoleni G
Fanetti AC
Dal Maso L
Source :
Cancer medicine [Cancer Med] 2021 Oct; Vol. 10 (19), pp. 6855-6867. Date of Electronic Publication: 2021 Sep 17.
Publication Year :
2021

Abstract

Background: The number of patients living after a cancer diagnosis is increasing, especially after thyroid cancer (TC). This study aims at evaluating both the risk of a second primary cancer (SPC) in TC patients and the risk of TC as a SPC.<br />Methods: We analyzed two population-based cohorts of individuals with TC or other neoplasms diagnosed between 1998 and 2012, in 28 Italian areas covered by population-based cancer registries. Standardized incidence ratios (SIRs) of SPC were stratified by sex, age, and time since first cancer.<br />Results: A total of 38,535 TC patients and 1,329,624 patients with other primary cancers were included. The overall SIR was 1.16 (95% CI: 1.12-1.21) for SPC in TC patients, though no increase was shown for people with follicular (1.06) and medullary (0.95) TC. SPC with significantly increased SIRs was bone/soft tissue (2.0), breast (1.2), prostate (1.4), kidney (2.2), and hemolymphopoietic (1.4) cancers. The overall SIR for TC as a SPC was 1.49 (95% CI: 1.42-1.55), similar for all TC subtypes, and it was significantly increased for people diagnosed with head and neck (2.1), colon-rectum (1.4), lung (1.8), melanoma (2.0), bone/soft tissue (2.8), breast (1.3), corpus uteri (1.4), prostate (1.5), kidney (3.2), central nervous system (2.3), and hemolymphopoietic (1.8) cancers.<br />Conclusions: The increased risk of TC after many other neoplasms and of few SPC after TC questions the best way to follow-up cancer patients, avoiding overdiagnosis and overtreatment for TC and, possibly, for other malignancies.<br /> (© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)

Details

Language :
English
ISSN :
2045-7634
Volume :
10
Issue :
19
Database :
MEDLINE
Journal :
Cancer medicine
Publication Type :
Academic Journal
Accession number :
34533289
Full Text :
https://doi.org/10.1002/cam4.4193